[Congressional Record Volume 167, Number 145 (Tuesday, August 10, 2021)]
[Senate]
[Page S6400]
From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]

  SA 3707. Ms. HASSAN submitted an amendment intended to be proposed by 
her to the concurrent resolution S. Con. Res. 14, setting forth the 
congressional budget for the United States Government for fiscal year 
2022 and setting forth the appropriate budgetary levels for fiscal 
years 2023 through 2031; which was ordered to lie on the table; as 
follows:

       At the end of title III, add the following:

     SEC. 3___. RESERVE FUND RELATING TO ELIMINATING FEDERAL 
                   WAIVER REQUIREMENTS FOR PRESCRIBING 
                   BUPRENORPHINE.

       The Chairman of the Committee on the Budget of the Senate 
     may revise the allocations of a committee or committees, 
     aggregates, and other appropriate levels in this resolution, 
     and make adjustments to the pay-as-you-go ledger, for one or 
     more bills, joint resolutions, amendments, amendments between 
     the Houses, motions, or conference reports relating to 
     expanding access to medication-assisted treatment, which may 
     include eliminating Federal waiver requirements for the 
     prescribing of buprenorphine as treatment for substance use 
     disorder, by the amounts provided in such legislation for 
     those purposes, provided that such legislation would not 
     increase the deficit over the period of the total of fiscal 
     years 2022 through 2031.
                                 ______